ABCL News and Press, AbCellera Biologics Inc. From 05/03/21

I operate two main portfolios: my "safe" portfolio and my high growth portfolio. This article will dissect and focus on my high-growth holdings. I generally like to invest in themes and tend to take a shotgun approach to my holdings in emerging sectors. I will list my holdings for 8 s...

380,000 square feet of facilities envisioned as creative tech hub where leading software, engineering, and bioscience talent can solve key problems to accelerate the discovery of new antibody treatments AbCellera (Nasdaq: ABCL), a technology company that has developed a cent...

AbCellera (Nasdaq: ABCL) will announce its first-quarter 2021 financial results on Thursday, May 13, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live webcast will be available on AbCellera’s Investor Relatio...

AbCellera (ABCL) and Empirico announce that they have entered into a strategic multi-target discovery collaboration to develop and commercialize novel antibodies.Empirico will use its Precision Insights Platform, a human genetics-focused discovery platform, to select up to five...

AbCellera (Nasdaq: ABCL) and Empirico Inc. (“Empirico”) announced today that they have entered into a strategic multi-target discovery collaboration. Through each company’s proprietary technologies, the multi-target collaboration leverages hyper-scale datase...

- Bamlanivimab (LY-CoV555) has greater affinity and potency relative to other RBD-binding and ACE2-blocking antibodies tested in this study - Because of its potency, bamlanivimab provides a therapeutic foundation to be administered with another antibody to expand the protectio...

Do You Have These Top Health Care Stocks On Your April Watchlist? With the Biden administration rolling out its infrastructure proposal, the American Jobs Plan on Wednesday, things do look promising for health care stocks . You might be asking, how does this relate to health car...

AbCellera ([[ABCL]] +3.1%) announces agreements to expand its collaboration with Gilead Sciences including a multi-year, multi-target antibody discovery collaboration and access to the company's humanized mouse technology, the Trianni Mouse.Under the financial terms of the agreements, Ab...

Expanded collaboration includes an eight-target discovery partnership leveraging AbCellera’s entire technology stack, including the Trianni Mouse® and the OrthoMab TM bispecific platforms AbCellera (Nasdaq: ABCL) today announced agreements to expand its c...

Sonoma Pharmaceuticals (SNOA) +28% on agreement with EMC pharma.Future FinTech Group (FTFT) +24% on acquiring bitcoin mining farm.AeroCentury (ACY) +22%.Jaguar Health (JAGX) +19% on FY results.P&F Industries (PFIN) +21%.AgEagle Aerial Systems (UAVS) +19% on FY results....